Posted by Michael Wonder on 06 Oct 2022
Lilly receives US FDA fast track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related co-morbidities
6 October 2022 - The fast track designation accelerates tirzepatide's path to US FDA submission for the treatment of adults with obesity, or overweight with weight-related co-morbidities
Eli Lilly announced today that the US FDA has granted fast track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related co-morbidities.
